Holen Sie sich die Stockscreener-App
67.52
2.81%
-1.8851
Schlusskurs vom Vortag:
$69.41
Offen:
$68.29
24-Stunden-Volumen:
451.00K
Relative Volume:
0.42
Marktkapitalisierung:
$11.70B
Einnahmen:
$8.42B
Nettoeinkommen (Verlust:
$1.52B
KGV:
7.773
EPS:
8.6871
Netto-Cashflow:
$56.00M
1W Leistung:
-7.59%
1M Leistung:
-13.59%
6M Leistung:
-7.46%
1J Leistung:
-13.44%
1-Tages-Spanne:
$66.61
$68.58
1-Wochen-Bereich:
$66.61
$72.16
52-Wochen-Spanne:
$60.70
$88.20
Solventum Corp Stock (SOLV) Company Profile
Firmenname
Solventum Corp
Sektor
Telefon
651-733-1110
Adresse
C/O 3M COMPANY, ST. PAUL
Compare SOLV vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SOLV
Solventum Corp
|
67.46 | 12.04B | 8.42B | 1.52B | 56.00M | 8.6871 |
|
ISRG
Intuitive Surgical Inc
|
486.65 | 174.07B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
164.22 | 47.54B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
80.47 | 39.64B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
RMD
Resmed Inc
|
251.57 | 36.84B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
43.20 | 35.57B | 28.43B | 1.16B | 1.26B | 1.4457 |
Solventum Corp Stock (SOLV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-26 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2026-01-20 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-12-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-09-11 | Eingeleitet | Jefferies | Hold |
| 2025-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Argus | Hold → Buy |
| 2025-06-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-05-19 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2024-09-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-09-05 | Eingeleitet | BTIG Research | Neutral |
| 2024-06-24 | Eingeleitet | Argus | Hold |
| 2024-05-30 | Eingeleitet | Goldman | Sell |
| 2024-05-10 | Eingeleitet | BofA Securities | Neutral |
| 2024-04-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-04-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-04-02 | Eingeleitet | Edward Jones | Hold |
Alle ansehen
Solventum Corp Aktie (SOLV) Neueste Nachrichten
Solventum’s Post-Spin Discount Looks Big, But Growth Must Show Up - Finimize
A Look At Solventum (SOLV) Valuation After Q4 2025 Earnings Beat And 2026 Outlook Update - simplywall.st
Bryan Hanson Leads Solventum to Success - Medical Device and Diagnostic industry
Solventum outlines 2026 organic sales growth of 2%-3% while advancing portfolio optimization and margin expansion - MSN
Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth - Finviz
Solventum Corp. stock falls Tuesday, underperforms market - MarketWatch
Solventum (SOLV) is Among the Highest-Rated Value Stocks: Is It Worth Purchasing? - Bitget
SOLV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Commit To Purchase Solventum At $65, Earn 11.6% Annualized Using Options - Nasdaq
Solventum : Shareholder Letter Q4 2025 - marketscreener.com
Solventum Stock: Improvements Come Slow (NYSE:SOLV) - Seeking Alpha
Solventum Corp. stock falls Monday, underperforms market - MarketWatch
UBS Adjusts Solventum Price Target to $82 From $79, Maintains Neutral Rating - marketscreener.com
Solventum’s High-Stakes Restructuring: Profitability Ambitions Face Significant Execution Risks - The Globe and Mail
Solventum Corporation (SOLV) Stock Analysis: A 21% Upside Potential Amidst Mixed Signals - DirectorsTalk Interviews
Solventum Corporation $SOLV Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Will Solventum's (SOLV) $1 Billion Buyback and Strong 2025 Earnings Redefine Its Capital Story? - Sahm
Solventum Earnings Call Balances Growth With Headwinds - TipRanks
Solventum Sets Confident Course with Strategic Overhaul and 2026 Guidance - AD HOC NEWS
SOLV PE Ratio & Valuation, Is SOLV Overvalued - Intellectia AI
A Look At Solventum (SOLV) Valuation After Earnings Beat Buyback Plan And Growth Guidance - Yahoo Finance
Andra AP fonden Has $8.04 Million Holdings in Solventum Corporation $SOLV - MarketBeat
Solventum Q4 Earnings Call Highlights - MarketBeat
Is It Time To Reassess Solventum (SOLV) After The 3M Separation? - simplywall.st
US Bancorp DE Has $31.04 Million Stock Position in Solventum Corporation $SOLV - MarketBeat
Solventum (NYSE:SOLV) Rating Increased to Buy at Wall Street Zen - MarketBeat
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know - The Globe and Mail
Piper Sandler reiterates Solventum stock rating on revenue growth By Investing.com - Investing.com South Africa
Solventum Q4 FY25 slides: organic growth solid despite earnings miss By Investing.com - Investing.com Australia
Solventum (SOLV) One Off US$1.5b Gain Raises Questions For Bullish Margin Narratives - simplywall.st
Solventum Corp. stock falls Friday, underperforms market - MarketWatch
SOLV: BTIG Reiterates 'Buy' Rating with Price Target Unchanged a - GuruFocus
Solventum Dental Solutions Sales Grow 8.6% in Q4 - Orthodontic Products
Solventum Corp SEC 10-K Report - TradingView
Solventum (NYSE:SOLV) Given New $83.00 Price Target at Wells Fargo & Company - MarketBeat
Solventum Stock Down Despite Q4 Earnings & Revenues Beat, Margins Down - Yahoo Finance
Solventum Corp (SOLV) Shares Gap Down to $74.47 on Feb 27 - GuruFocus
Solventum Beat Wall Street Earnings Estimates. The Stock Is Down. - Barron's
Solventum (SOLV) Maintains Overweight Rating with Raised Price T - GuruFocus
Solventum (NYSE:SOLV) Stock Price Expected to Rise, KeyCorp Analyst Says - MarketBeat
Solventum (NYSE:SOLV) Given Buy Rating at BTIG Research - MarketBeat
Piper Sandler reiterates Solventum stock rating on revenue growth - Investing.com
Solventum Beat Wall Street Earnings Estimates. The Stock Falls. - Barron's
KeyBanc Adjusts Price Target on Solventum to $99 From $97, Maintains Overweight Rating - marketscreener.com
Demystifying Solventum: Insights From 5 Analyst Reviews - Benzinga
Jefferies Adjusts Price Target on Solventum to $84 From $75, Maintains Hold Rating - marketscreener.com
Solventum beats quarterly estimates on strong demand for surgical products - WHTC
Solventum (SOLV) Q4 2025 Earnings Call Transcript - Fortune
Solventum exceeds earnings estimates in first year as solo company - MassDevice
Solventum (NYSE:SOLV) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Solventum: Q4 Earnings Snapshot - theheraldreview.com
Finanzdaten der Solventum Corp-Aktie (SOLV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):